Philips’ Subsidiary To Pay Over $24M For Alleged False Claims For Respiratory-Related Equipment
Koninklijke Philips NV (NYSE:PHG) has agreed to pay over $24 million to resolve alleged false claims over respiratory-related medical…
Judge Issued Favorable Decision To Illumina In FTC Challenge Regarding $8B Grail Acquisition
Illumina Inc (NASDAQ:ILMN) said it received a favorable initial decision from the judge overseeing the U.S. Federal Trade Commission’s challenge to…
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002,…
FDA Advisory Committee Meeting Scheduled For October 28, 2022 To Review Y-mAbs’ Refiling For Omburtamab
The Oncologic Drugs Advisory Committee (ODAC) of the U.S.
Intellia Gets FDA Orphan Drug Status For Hereditary Angioedema Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ: NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE).
NTLA-2002 is currently being evaluated in a Phase 1/2 study in adults with Type I or Type II HAE.
Europe Backs Approval Of Omicron-Adapted COVID-19 Vaccines
Health Canada has approved Moderna Inc's (NASDAQ:
Stryker Unveils New Gamma4 Hip Fracture Nailing System
Stryker Corporation (NYSE:SYK) has launched the Gamma4 System to provide surgeons with the next generation of Stryker’s intramedullary nailing system. The…
Nevro Wins Multiple Coverage Options For Spinal Cord Stimulation In Diabetic Neuropathy
Nevro Corp (NYSE:NVRO) announced positive updates to multiple spinal cord stimulation (SCS) coverage policies. Aetna’s new SCS policy explicitly covers PDN…
Werewolf Shares Climb As Initial-Stage Solid Tumors Study Kicks-off
Werewolf Therapeutics (NASDAQ: HOWL) has initiated patient dosing in a Phase 1/1b clinical trial evaluating WTX-124, its lead INDUKINET molecule targeting IL-2 for the treatment of solid tumors.
BARDA Backs Arcturus’ Influenza Vaccine Program
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) received an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority…